Segment Information

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Reporting Disclosure

SEGMENT INFORMATION

We have one operating segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Therefore, our results of operations are reported on a consolidated basis consistent with internal management reporting reviewed by our chief operating decision maker, who is our chief executive officer. Enterprise-wide disclosures about product sales, revenues and long-lived assets by geographic area, and revenues from major customers are presented below.

Product Sales

Our product sales consist of the following (in millions):

	Year Ended December 31,
	2017		2016		2015
Antiviral products:
Harvoni	$	4,370	$	9,081	$	13,864
Genvoya	3,674		1,484		45
Epclusa	3,510		1,752		—
Truvada	3,134		3,566		3,459
Atripla	1,806		2,605		3,134
Descovy	1,218		298		—
Stribild	1,053		1,914		1,825
Viread	1,046		1,186		1,108
Odefsey	1,106		329		—
Complera/Eviplera	966		1,457		1,427
Sovaldi	964		4,001		5,276
Vosevi	293		—		—
Other antiviral	196		72		69
Total antiviral products	23,336		27,745		30,207
Other products:
Letairis	887		819		700
Ranexa	717		677		588
AmBisome	366		356		350
Zydelig	149		168		132
Other products	207		188		174
Total product sales	$	25,662	$	29,953	$	32,151

Revenues by Geographic Region

The following table summarizes total revenues from external customers and collaboration partners by geographic region (in millions). Product sales and product-related contract revenue are attributed to regions based on ship-to location. Royalty and non-product related contract revenue are attributed to regions based on the location of the collaboration partner.

	Year Ended December 31,
	2017		2016		2015
Revenues:
United States	$	18,194	$	19,354	$	21,234
Europe	5,311		6,365		7,528
Other countries	2,602		4,671		3,877
Total revenues	$	26,107	$	30,390	$	32,639

Long-lived Assets

The net book value of our property, plant and equipment (less office and computer equipment) in the United States was $2.6 billion as of December 31, 2017, $2.2 billion as of December 31, 2016 and $1.8 billion as of December 31, 2015. The corresponding amount in international locations was $520 million as of December 31, 2017, $430 million as of December 31, 2016 and $334 million as of December 31, 2015. All individual international locations accounted for less than ten percent of the total balances.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

	Year Ended December 31,
	2017		2016		2015
McKesson Corp.	23	%	22	%	24	%
AmerisourceBergen Corp.	20	%	18	%	19	%
Cardinal Health, Inc.	19	%	16	%	15	%